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Twenty-five whole-organ recipients treated from 
1981 through September 1988 were HIV carriers. 
Eleven were infected before transplantation, although 
this was not known until later in 8 recipients. The other 
14 were infected perioperatively. Ten of the 25 recipi-
ents were infants or children. The organs transplanted 
were the liver (n = 15), and the heart or kidney (n = 5, 
each). After a mean follow-up of 2.75 years (range, 0.7-
6.6 years), 13 recipients are alive. Survival is 7/15, 2/ 
5, and 4/5 of the liver, heart, and kidney recipients, 
respectively. The best results were in the pediatric 
group (70% survival) in which only 1 of 10 patients died 
of AIDS. In contrast, AIDS caused the death of 5 of 15 
adult recipients and was the leading cause of death. 
Transplantation plus immunosuppression appeared to 
shorten the AIDS-free time in HIV+ patients as com-
pared to nontransplant hemophiliac and transfusion 
control groups. Accrual of HIV+ transplant recipients 
has slowed markedly since the systematic screening of 
donors, recipients, and blood products was begun in 
1985. 
Human immunodeficiency virus has been a subject of concern 
in transplantation (1, 2) since the infection became a known 
clinical entity. It was anticipated that transplant patients would 
be at high risk of HIV infection because of their exposure to 
blood, blood components, and other sources of HIV infection. 
However, the extent of the problem was not known until 
demographic studies were performed by Dummer et al. (3) who 
examined the stored and current sera of 1043 patients treated 
with organ transplantation at the University of Pittsburgh from 
1981 to 1986. They found that 1.7% of the recipients were 
either HIV+ at the time of transplantation or seroconverted 
soon after. Pediatric patients had an unusually high risk (2.3%). 
Similar disquieting statistics have been reported from single 
centers (4, 5) and from multiinstitutional collaborations (6-8). 
Although this was not the intention, a clinical experiment 
was created by the presence of this pool of HIV+ transplant 
recipients, many of whom now have lived for years under 
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posttransplant immunosuppression. The records of these pa-
tients were studied with particular emphasis to their clinical 
course, long-term survival, and current status. 
MATERIALS AND METHODS 
Transplantation patients. Of 3023 transplant recipients treated at 
the University of Pittsburgh between January 1, 1981 and September 
5, 1988, 25 were found to be HIV+ and are included in this report. 
Eighteen of these patients were found to be positive in a look-back 
epidemiologic study performed at our center (3). The other 7 have been 
diagnosed since this study was completed. Two of the 17 male patients 
had a history of sexual contact with other men. 
Two groups of HIV+ transplant recipients were identified: those who 
were HIV+ at the time of transplantation (prevalent group) and those 
who seroconverted to HIV after transplantation (seroconverter group). 
HIV+ patients were those whose sera were positive for antibody to 
HIV -1 by enzyme immunoassay (LA V -EIA; Genetic Systems, Seattle, 
W A) and confirmed by Western blot (Immunoblot; Biorad, Richmond, 
CAl. The serologic findings in all HIV+ patients have been confirmed 
with multiple testing. Universal HIV testing of all blood and tissue 
donors has been implemented in Pittsburgh since March 1985. Screen-
ing for HIV of recipients as a condition for candidacy has been routine 
since the summer of 1985. 
Patients were defined as having AIDS if they met the Centers for 
Disease Control" (CDC)' criteria for AIDS (9). All AIDS defining 
complications were attributed to HIV alone even though these same 
infections occur frequently after transplantation without AIDS (10). 
All patients received CsA and prednisone as maintenance immuno-
suppression. Polyclonal antilymphocyte globulin (Stanford ALG) was 
used for heart recipients. Monoclonal OKT3 was used for kidney and 
liver recipients after November 1984 (J 1). Azathioprine was given to 
13 of the 25 patients. Bactrim and Acyclovir prophylaxis has been used 
since mid-1987, but only 2 new HIV+ patients were accrued subse-
quently_ 
Information regarding the type of immunosuppressive therapy re-
ceived, the incidence and type of rejection, other complications, long-
term survival and current condition, graft function, social status, and 
general health was also collected. Graft failure in the case of kidney 
recipients was defined by the need to return to dialysis. In the case of 
liver and heart transplant recipients, all surviving patients had normal 
graft function, obviating the need for further categorization of trans-
plant results. 
Control groups. Two HlV+ control groups of age-matched nonim-
munosuppressed patients with known seroconversion dates were ob-
tained. The first control group consisted of 28 hemophiliac patients 
cared for (12) at the Hemophilia Center of Western Pennsylvania.9 
The second consisted of 42 patients collected at the CDC who were 
known to have been accidentally infected by a blood transfusion (J,'J). 
8 Centers for Infectious Disease Centers for Disease Control, United 
States Public Health Service Department of Health and Human Serv-
ices, Atlanta, GA 20333. 
• Abbreviation: CDC, Centers for Disease Control. 
9 The Hemophilia Center of Western Pennsylvania 812 Fifth Ave-
nue, Pittsburgh, PA 15219. 
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We also compared the survival of our HIV+ transplant recipients to 
that of 1303 consecutive liver recipients treated between January 1, 
1980 and September 5,1988 (14). 
Statistical methods. Seroconversion dates for the transfusion and 
transplantation HIV seroconverter groups were taken as the day of 
transfusion or transplantation. Seroconversion dates for the hemophil-
iac group were estimated as the midpoint between last negative and 
first positive serum samples. All follow-ups were to March 1, 1989. 
Patients who did not develop AIDS but died, contributed AIDS-free 
time until their death. Similarly, patients who eventually developed 
lethal AIDS complications contributed variable amounts of AIDS-free 
time before the onset of these complications. 
Statistical analysis utilized BMDP Statistical Software to generate 
Kaplan-Meier product-time estimations for both survival and AIDS-
free time. The Breslow generalized Wilcoxon test was used for infer-
ences of statistical significance. 
RESULTS 
Of the 25 HIV+ transplant recipients, 11 were prevalent, and 
14 were seroconverters. Seventeen were male, and 8 were fe-
male. Three patients underwent transplantation despite their 
known HIV+ status. Their treatment reflected an institutional 
policy of not allowing HIV+ status as a sale factor to rule out 
organ-transplant candidacy. 
Survival 
Of the 25 patients, 13 (52%) are alive (Tables 1 and 2). 
Survival is the same in males (53%) as in females (50%). 
Survival by organ. Seven (47%) of the 15 liver recipients are 
alive as well as 4 (80%) of 5 kidney recipients, and 2 (40%) of 
5 heart recipients. Mean follow-up in the liver survivors is 4.5± 
2.1 SD years (range, 2/1-6.5). Mean follow-up in the kidney 
survivors is 3.4±2.2 SD years (range, 1.0-5.0). The 2 heart 
recipients have lived for 6.6 and 2.2 years. Because the majority 
of the HIV+ transplant patients were liver transplant recipients, 
the survival of the HIV patients was compared to the overall 
liver transplant (n = 1303) survival in our CsA experience of 
1980-1988 (Fig. 1). Survival was practically identical at 1 year. 
Subsequent survival at 2, 4, and 5 years was lower in the HIV+ 
group although it never reached statistical significance. Five-
year survival was 63% in the reference population compared to 
53% in the HIV+ group. 
Prevalent HIV+ versus seroconverters. The survival was not 
different in the seroconverter and prevalent transplantation 
groups (Fig. 2) at any point up to and including 5 years after 
transplantation (P = 0.69). 
The 11 patients who were HIV+ at the time of transplantation 
(7 livers, 3 kidneys, 1 heart) are listed individually in Table 1. 
Six (54%) ofthese patients are alive after a mean 3.3±2.3 (SD) 
years (range, 0.7-5.7). All 5 of the deaths were of liver recipi-
ents, and 3 of them were AIDS related (Table 1). 
Seven (50%) of the 14 patients who seroconverted to HIV+ 
after transplantation are alive (Table 2) after 4.8±1.8 (SD) 
years (range, 2.1-6.6) including 5 of 8 liver recipients, 1 of 2 
kidney recipients, and 1 of 4 heart recipients. One of the 
surviving liver recipients received a graft from an HIV+ donor 
and seroconverted between 30 and 80 days after transplantation 
(15). This patient is alive 2.6 years after transplantation. Ten 
months ago, he developed a rectal carcinoma that was consid-
ered a complication of his preexisting ulcerative colitis. He was 
treated with total protocolectomy and is well. Of the 7 deaths, 
3 were AIDS related with 1 example each among the liver, 
kidney, and heart recipients (,rable 2). 
Pediatric versus adult. The 10 children had a mean age of 
7.8±6.2 (SD) years at the time of liver (n = 7), kidney (n = 2), 
and heart transplantation (n = 1). Seven (70%) are alive after 
4.7±1.8 (SD) years (range, 2.1-6.5). Three pediatric liver recip-
ients died, 1 at 5 months from a ruptured hepatic-artery aneu-
rysm, another at 9 months from a preexisting nervous system 
disorder. The third death at 3.5 years from a systemic CMV 
infection was attributed to AIDS. One of the pediatric renal 
recipients was returned to dialysis when the kidney was rejected 
after 8 months, but the patient is otherwise well (Table 1). 
The results were worse in the adults, mean age of 4:i.1±9.2 
(SD) years of whom only 6 (40%) are alive 3.5±2.4 SD years 
after transplantation (range, 0.7-6.6). The mortality was organ 
related: with 1 (25%) death after 4 kidney transplantations, 3 
(75%) of 4 after heart transplantation, and 5 (63%) of 8 after 
liver transplantation. Five of these deaths were from AIDS 
(Tables 1 and 2). 
Correlations of rejection and immunosuppression. Treatment 
was started with CsA and prednisone in 12 patients of whom 5 
are still alive. Rejection was diagnosed in 8 of them. Azathi-
oprine was also used from the outset in the other 13, and 8 
TABLE l. Transplant recipients who were HIV+ before transplantation 
Patient Organ" Age (years) 
la H 15 
2a L 48 
3a K 29 
4a K' 16 
5a K 64 
6a L 15 
7a L 48 
Sa L 0.5 
9a L 32 
lOa L 42 
lla L 3 
a Abbreviations: L, liver; H, heart; K, kidney. 
b Time from first transplant. 
Current Survival 
status time b 
Alive 26 months 
Alive 8 months 
Alive 5 years 
Alive 5 years, 5 months 
Alive 1 year 
Dead 3 years, 6 months 
Dead 4 months 
Dead 9 months 
Dead 18 months 
Dead 6 months 
Alive 5 years, 8 months 
--------
'Currently on dialysis, kidney graft lost to acute rejection 8 months after transplant. 
d PCP: Pneumocystis carinii. 
C CNS: central nervous system. 
-----
No. Cause ur 
transplants death 
-------
1 
1 
CMV 
1 PCP" 
2 Preexisting CNS disease" 
Immunoblastic sarcoma 
2 Colchichine toxicity 
3 
- ----- --
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TABLE 2. Transplant recipients who seroconverted after transplantation 
Patient Organ Age Current Survival No. Cause of (years) status time" transplants death b 
Ib K 38 Dead 5 months 1 Generalized TB 
2b K 13 Alive 25 months 2 
3b L 46 Dead 4 months 2 HAT 
4b L 5 Alive 6 years, 6 months 
5b L 44 Dead 5 years, 1 month 1 Pneumonitis of unknown cause 
6b L 5 Alive 5 years, 4 months 1 
7b L 3 Alive 5 years, 8 months 3 
8b L 2 Dead 5 months 2 HA aneurysm 
9b L 32 Alive 5 years, 2 months 1 
lOb H 42 Dead 15 months 1 PCP + List + TOX 
lIb H 53 Dead 4 months Heart failure 
12b H 34 Alive 6 years, 7 months 
13b H 47 Dead 5 months Heart failure 
14bc L 47 Alive 2 years, 7 months 
a Time from first transplant. 
b Abbreviations: TB, tuberculosis; HAT, hepatic artery thrombosis; HA, hepatic artery; PCP, Pneumocystis carinii; List, listeria monocytogenes 
meningitis; TOX, Toxoplasma gondii. 
c Received a liver allograft from an HIV+ donor and seroconverted after transplantation (15, see text). 
" § 
-----------'1 
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FIGURE l. Kaplan-Meier survival estimates comparing HIV- liver 
transplant recipients to HIV+ transplant recipients. 
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FIGURE 2. Kaplan-Meier survival estimates for HIV+ transplant 
recipients, Pittsburgh, PA. 
survived. Rejection was diagnosed in 9 of these recipients. Of 
the 17 patients who developed rejection in the foregoing 2 
groups, 10 (59%) died. Six (55%) of 11 patients given OKT3 or 
ALG died. Only 2 (25%) of 8 who did not develop rejection 
have died. 
Six liver recipients underwent retransplantation: 4 for he-
patic artery thrombosis, 1 for uncontrollable acute rejection, 
and 1 for chronic rejection. Two of these patients are still alive 
and well 5.7 years later. One renal recipient is well 1.8 years 
after a second transplant. 
AIDS-related morbidity and mortality. Six (24%) of the 25 
HIV+ transplant recipients (1 heart, 1 kidney, 4 livers) died of 
AIDS after 5 months to more than 5 years (Tables 1 and 2). 
Cause of death included Pneumocystis Carinii pneumonia (2 
cases), in 1 case coexisting with Listeria monocytogenes and 
Toxoplasmagondii meningitis, generalized tuberculosis (1 case), 
systemic cytomegalovirus (1 case), pneumonitis of unknown 
etiology (1 case), and immunoblastic sarcoma (1 case). 
One heart (patient la, Table 1) and 2 liver recipients (pa-
tient!:> 4b and 9b, Table 2) have been living with AIDS for 8, 
21, and 6 months, respectively. Two have interstitial pneumo-
nitis, and the other has oral and esophageal candidiasis and 
recurrent CMV infections. Posttransplantation follow-ups are 
2.2, 6.5, and 5.2 years. Patient 4b has had immunosuppression 
stopped for 18 months. Patients 1a and 9b have had immuno-
suppression drastically reduced. All 3 patients have normal 
graft function. 
The AIDS-free time after transplantation was not signifi-
cantly different in the prevalent versus the HIV seroconverters 
(Fig. 3). For this reason, the 2 transplant subgroups were 
combined for comparison with the 2 nontransplant control 
groups (Fig. 4). 
The AIDS-free times ofthe transplant recipients were poorer 
than in the blood-transfusion and hemophiliac control groups 
in that the transplant patients had more-frequent early devel-
opment of AIDS. Four of 25 transplant recipients developed 
AIDS within the first 15 months, compared to 0 and 1 example 
in the 2 control groups (P = 0.04, Fisher's exact test). However, 
beyond 15 months, the slope of the curves was similar in all 3 
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FIGURE 3. Kaplan-Meier estimates for the proportion of HIV+ 
transplant recipients who remain AIDS free. 
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FIGURE 4. Kaplan-Meier estimates for the proportion remaining 
AIDS free comparing HIV+ transplant recipients to hemophiliacs and 
transfusion recipients. 
groups, and for the 5-year period approached statistical signif-
icance (P = 0.065). 
Rehabilitation after transplantation. Nine of the 13 surviving 
patients are working full time or at school. Three more live at 
home but are not able to work. One of the surviving patients is 
currently hospitalized with recurrent hepatitis B. 
DISCUSSION 
Candidates for transplantation of any of the vital organs 
apparently have a higher rate of HIV+ serology than the general 
population (3-8). Patients with vital organ failure are exposed 
to the virus in blood components, transplanted tissues, unsterile 
needles, and HIV+ patients who are concentrated in hospitals 
and clinics (3, 15-18). Whether or not the HIV+ patients with 
organ failure should be excluded from transplant candidacy if 
their positive HIV status is known remains a debatable issue, 
mainly due to the paucity of scientific data about subsequent 
survival. 
When screening tests for this disease became generally avail-
able in the spring of 1985, HIV infections in kidney recipients 
were described almost immediately (1, 2). These reports em-
phasized the consequent morbidity and high mortality rates 
(7). However, the single institutional series of Dummer et al. 
(3) and multicenter studies (6) have shown that early AIDS 
and death may not be the inevitable or even the usual outcome 
after transplantation under immunosuppression. 
Almost certainly, the presence of HIV antibodies would have 
precluded candidacy if the diagnosis in the cases cited above 
from the literature and most of those reported herein had been 
made in advance. In retrospect, the majority have benefited 
from transplantation, although the follow-up is limited to a few 
years. Children have been particularly hardy in that only 1 in 
10 has died of what was defined as an AIDS-related complica-
tion, namely a cytomegalovirus infection 31f2 years postopera-
tively. The results in adults were worse in that AIDS was the 
most important cause of mortality. The risk was greatest with 
the more-complex liver and heart transplantations, and least 
with the kidney. 
With these findings, it was not surprising that the 5-year 
survival rate after transplantation of HIV+ recipients was 11 % 
lower than in the HIV- liver patients. The difference was not 
statistically significant because of the small HIV+ sample, but 
there was evidence that the immunosuppression due to HIV+ 
status and immunosuppression for transplantation could be 
more dangerous than either factor alone during the first post-
operative year. During this time, manifestations of AIDS in 
organ recipients (all organs) developed at an accelerated rate 
compared to HIV+ patients in the 2 control groups. After 15 
months, this extra risk was no longer apparent. 
As risk factors with high predictive value for subsequent 
AIDS are delineated (19-25), we should be able to better define 
which of the HIV+ transplant candidates have a reasonable 
prospect of benefitting from transplantation. It already is ob-
vious that transplantation is medically contraindicated in pa-
tients who have AIDS or signs and symptoms of impending 
AIDS. 
How to apply this information in future case selection may 
depend more on philosophic persuasions than scientific ones 
since no form of treatment can provide perpetual life. In HIV+ 
patients who have no evidence of AIDS, transplantation can 
prolong meaningful life in the majority of patients but less 
reliably and less safely than in HI V- recipients. It is self-
evident that the same statement could be made about virtually 
every other major medical or surgical therapy available today. 
Such therapies are not withheld from HIV+ patients because 
of a predictably lower efficiency or because of high cost (26-
28). The rationing of transplantation services to exclude 
asymptomatic HIV+ patients from candidacy for such reasons 
or even because of a potential shortage of organs would be a 
departure from past practices that will have to be carefully 
considered and decided upon by each individual center. 
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